TURNOVER (x1000 SEK)
NET PROFIT (x1000 SEK)
EMPLOYEES
Sprint Bioscience AB
Closing information (x1000 SEK)
| Closing information | 2024/12 | 2023/12 | 2022/12 |
| Turnover |
65,641
|
50,485
|
83 |
| Financial expenses |
40
|
387
|
1 |
| Earnings before taxes |
-18,277
|
-438
|
-60,170 |
| EBITDA |
-18,710
|
-398
|
-60,122 |
| Total assets |
42,055
|
62,377
|
37,422 |
| Current assets |
37,243
|
57,872
|
34,882 |
| Current liabilities |
32,783
|
34,603
|
9,234 |
| Equity capital |
9,272
|
27,774
|
28,188 |
| - share capital |
6,982
|
6,982
|
6,980 |
| Employees (average) |
37
|
28
|
34 |
Financial ratios
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Solvency |
22.0%
|
44.5%
|
75.3% |
| Turnover per employee |
1,774
|
1,803
|
2 |
| Profit as a percentage of turnover |
-27.8%
|
-0.9%
|
-72494.0% |
| Return on assets (ROA) |
-43.4%
|
-0.1%
|
-160.8% |
| Current ratio |
113.6%
|
167.2%
|
377.8% |
| Return on equity (ROE) |
-197.1%
|
-1.6%
|
-213.5% |
| Change turnover |
15,156
|
50,402
|
-35,031 |
| Change turnover % |
30%
|
60725%
|
-100% |
| Chg. No. of employees |
9
|
-6
|
3 |
| Chg. No. of employees % |
32%
|
-18%
|
10% |
Total value of public sale
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.